Selene: a two-component pairing and its evidence limits

A woman standing in soft window light against a warm limestone wall

Selene is a named combination of GHK-Cu and tesamorelin. One component comes from copper peptide skin research and the other has an FDA-approved product in one narrow indication. No study of the pairing was identified.

Composition

  • ghk-cu
  • tesamorelin

Overview

This is a two-component grouping, which makes the evidence discussion unusually clean. Tesamorelin is the only substance across this entire stack library with a current FDA-approved product, and that approval covers reduction of excess abdominal fat in people with HIV-associated lipodystrophy. GHK-Cu's published work is largely topical. Pairing them is a theme rather than a tested proposition.

Why these are grouped

The rationale offered is that skin and tissue signalling might be discussed alongside body composition. There is no published work testing whether the two components interact usefully, and neither one's evidence base transfers to the other's purpose.

What each ingredient contributes

ghk-cu

A copper-binding peptide with published skin remodelling and wound research, largely topical rather than systemic.

tesamorelin

A growth hormone releasing hormone analogue with an FDA-approved product for one specific indication that does not extend to general use.

Combination evidence

  • No published or registered study of the pairing was identified.
  • Tesamorelin's approval covers a specific population and indication and says nothing about this pairing.
  • No safety data describe the two used together.

Tesamorelin's trial record is real and narrow. GHK-Cu's is real and mostly topical. Neither supports the other's use, and neither supports the pairing.

Preclinical rationale

  • Copper peptides appear in skin remodelling and wound healing research.
  • Growth hormone releasing analogues have human data on visceral fat in a defined clinical population.

What is not established

  • Any effect of the pairing on skin, aging, or body composition in the general population.
  • Whether systemic GHK-Cu reproduces topical findings.
  • Safety of the pairing at any duration.

Questions to discuss with a physician

  • Does tesamorelin's approved indication have anything to do with my situation?
  • Is there a reason to combine rather than consider one component?
  • What laboratory work would you want first?
  • What would you monitor and when would you stop?
  • What should I not expect?

This page is educational. Nothing here can be ordered, and nothing here is a prescription or medical advice. Compounded preparations are not FDA-approved. To ask about current availability, visit goal.md/peptides/connect or call or text 314-907-3103.

Medically reviewed by Michael Fitch, MD, MD. Last reviewed 2026-08-15.